Valeant Pharmaceuticals International Extends Contract with J. Michael Pearson as CEO and Appoints Him as Chairman of the Board
"I am honored that the Board has shown its confidence in me with this appointment and that by extending my contract, allows me the privilege of leading this organization for the next six years," stated J. Michael Pearson, chairman and chief executive officer. "I continue to believe in Valeant's long-term potential and I look forward to working with our team to execute on our strategy to become a leading specialty pharmaceutical company."
About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. More information about Valeant can be found at www.valeant.com.
Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com
(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)
SOURCE Valeant Pharmaceuticals International, Inc.